KM Research Hub
← 返回论文库
待处理 入排:排除 图源:待检查 入排置信度 0.98

Phase III randomized clinical trial of efficacy and safety of amlodipine and candesartan cilexetil combination for hypertension treatment.

Moon-Seung Soh, Kyung-Heon Won, Jae-Joong Kim, Sung Yun Lee, Min Su Hyon, Ho-Joong Youn, Seung-Woon Rha, Doo-Il Kim, Youngkeun Ahn, Byung Jin Kim, Dong-Ju Choi, Jong-Seon Park, Dae-Kyung Kim, Woo-Jung Park, Hong-Seok Lim, Seung-Jea Tahk

Sci Rep 14(1) 22940

PMID39358448
PMCIDPMC11447083
DOI10.1038/s41598-024-74003-5
发表日期2024-10-02
入排依据:未发现恶性肿瘤人群证据。
摘要

摘要

Effective antihypertensive therapy is essential for achieving optimal blood pressure (BP) control and reducing cardiovascular events. This double-blind, multicenter, randomized trial aimed to compare the antihypertensive efficacy and safety of a combination of amlodipine (AML) and candesartan cilexetil (CC) versus AML monotherapy in patients with essential hypertension (HTN). After a 4-week run-in period with AML 5 mg, patients whose HTN remained uncontrolled (diastolic BP [DBP]) ≥ 90 mmHg and < 120 mmHg) were randomized to receive either AML + CC or AML alone for 8 weeks. Efficacy was assessed by measuring changes in DBP and systolic BP (SBP). The primary safety measure was the incidence of adverse events (AEs). A total of 174 participants were included in the efficacy analysis. After 8 weeks, DBP decreased by -9.92 ± 0.86 mmHg in the AML + CC arm and - 2.08 ± 0.86 mmHg in the AML arm (p < 0.0001). SBP decreased by -14.27 ± 1.39 mmHg in the AML + CC arm versus - 2.77 ± 1.39 mmHg in the AML arm (p < 0.0001). AEs occurred in 11.24% of the AML + CC group and 5.62% of the AML group (p = 0.1773). AML + CC combination therapy demonstrated superior efficacy with good tolerance, making it a promising option for patients with inadequately controlled hypertension on amlodipine alone.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。